Dr Ray brings a wealth of expertise in biopharmaceutical R&D is a highly accomplished industry leader with three decades of healthcare experience
CorEvitas welcomes Amrit Ray to its Board of Directors. CorEvitas is the built-for-purpose provider of gold-standard real-world evidence, striving to advance patient care by generating high quality curated data on newly approved therapies.
“I am honoured to join the Board of Directors of CorEvitas. With a 20-year track record of excellence in real-world evidence, CorEvitas is a visionary organisation. I have dedicated my professional career to advancing medical breakthroughs and championing healthcare access for patients, and CorEvitas is fundamentally driven by the same motivation. Drawing on speciality data sets, a unique understanding of regulatory needs, and unparalleled standards for data analytics, CorEvitas is driving forward the field of real-world evidence. I look forward to partnering with the Board and management team to help advance the company’s mission: to uncover deep clinical insights that lead to safer, more effective treatments and better patient care,” notes Dr Ray.
Dr Ray brings a wealth of expertise in biopharmaceutical R&D is a highly accomplished industry leader with three decades of healthcare experience. He currently serves as a Senior Advisor to Bain Capital Life Sciences, which invests in biopharma, medical devices, diagnostics, and technology companies that drive medical innovation. Previously, Dr Ray was Global President, R&D and Medical, and Executive Leadership Team member at Pfizer Upjohn, overseeing all Phase I-IV research and development, regulatory, safety and medical affairs for the organisation.
Before Pfizer, Dr Ray served as Chief Medical Officer and R&D Leadership Team Member for pharmaceuticals at Johnson & Johnson.
“CorEvitas continues to evolve as a global leader in real-world evidence. The future of this landscape includes a deeper, more holistic view of the patient and leverages real-world evidence to substantiate the health and safety of patients. Amrit’s experience, building patient focus and healthcare access while propelling forward research and innovation will be pivotal to our growth as an organisation,” said Raymond Hill, CEO and Chairman, CorEvitas.
CorEvitas continues to build a leading position in real-world evidence across registries, patient experience, electronic health records, claims and data analytics, as well as precision medicine and biorepository solutions.
Providing curated data while leveraging a cloud-based secure technology platform enables the company to aggregate and process longitudinal data at scale and handle a broad spectrum of clinical and patient-reported outcomes. The organisation is committed to ensuring the best therapies and care are delivered to the patients that need them the most.
Joe Rogers, MD, Audax Private Equity, shares, “Dr Ray is a renowned and experienced executive with a record of driving positive impact for patients and advancements for our healthcare system. His deep functional experience across R&D, medical affairs, and real-world evidence have contributed to advancing pipeline development while optimising patient impact across multiple therapeutic areas including oncology, immunology, and neuroscience to name a few. We anticipate his guidance and leadership in this space to have a significant impact on CorEvitas’ corporate strategy and growth trajectory.”
